Biotech Values

[genisi]

In EU, Fabrazyme and Replagal applications were submitted on the same week for EMEA approval and were approved on the same day with co-exclusivity marketing authorisations. In the US, applications were submitted on the same month but the FDA approved Fabrazyme first and with approval came orphan drug marketing exclusivity that TKT since had to break.